Finalizing display...
Ligand source activities (1 row/activity)
Ligands | Receptor | Activity | Chemical information | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Common name | GPCRdb ID | Reference ligand | Vendors | Species | Assay Type | Activity Type | Activity Relation | Activity Value | p-value (-log) | Fold selectivity | Tested GPCRs | Assay Description | Source | Mol weight | Rot Bonds | H don | H acc | LogP | Smiles | DOI | |
Ligands | Receptor | Activity | Chemical information | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Common name | GPCRdb ID | Reference ligand | Vendors | Species | Assay Type | Activity Type | Activity Relation | Activity Value | p-value (-log) | Fold selectivity | Tested GPCRs | Assay Description | Source | Mol weight | Rot Bonds | H don | H acc | LogP | Smiles | DOI | |
No data available in table |
Showing 0 to 0 of 0 entries
Ligands | Receptor | Activity | Chemical information | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Common name | GPCRdb ID | Reference ligand | Vendors | Species | Assay Type | Activity Type | Activity Relation | Activity Value | p-value (-log) | Fold selectivity | Tested GPCRs | Assay Description | Source | Mol weight | Rot Bonds | H don | H acc | LogP | Smiles | DOI | |
Ligands | Receptor | Activity | Chemical information | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Common name | GPCRdb ID | Reference ligand | Vendors | Species | Assay Type | Activity Type | Activity Relation | Activity Value | p-value (-log) | Fold selectivity | Tested GPCRs | Assay Description | Source | Mol weight | Rot Bonds | H don | H acc | LogP | Smiles | DOI | |
cromoglicic acid | 1208 | None | 41 | Human | Functional | pEC50 | = | - | 4.35 | -588 | 5 | Unclassified | Guide to Pharmacology | 468.1 | 8 | 3 | 9 | 2.11 | O=C(O)c1cc(=O)c2c(OCC(O)COc3cccc4oc(C(=O)O)cc(=O)c34)cccc2o1 | https://pubmed.ncbi.nlm.nih.gov/20022913 | |
isoprenaline | 2091 | None | 34 | Human | Functional | EC50 | = | 4.90 | 8.31 | -63 | 49 | Agonist activity at human TAS2R49 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assay | ChEMBL | 211.1 | 4 | 4 | 4 | 1.13 | CC(C)NCC(O)c1ccc(O)c(O)c1 | - | |
isoprenaline | 2091 | None | 34 | Human | Functional | pEC50 | = | 8.31 | 8.08 | -63 | 49 | Agonist activity at human TAS2R49 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assay | Drug Central | 211.1 | 4 | 4 | 4 | 1.13 | CC(C)NCC(O)c1ccc(O)c(O)c1 | - | |
methoxsalen | 2505 | None | 74 | Human | Functional | pEC50 | = | - | 4.92 | 3 | 2 | Unclassified | Guide to Pharmacology | 216.0 | 1 | 0 | 4 | 2.55 | COc1c2occc2cc2ccc(=O)oc12 | https://pubmed.ncbi.nlm.nih.gov/26501253 | |
ritanserin | 3332 | None | 53 | Human | Functional | pEC50 | = | - | 5.22 | -363 | 44 | Unclassified | Guide to Pharmacology | 477.2 | 5 | 0 | 5 | 5.48 | Cc1nc2sccn2c(=O)c1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1 | https://pubmed.ncbi.nlm.nih.gov/26501253 | |
tobramycin | 3840 | None | 0 | Human | Functional | pEC50 | = | - | 4.29 | - | 1 | Unclassified | Guide to Pharmacology | 467.3 | 6 | 10 | 14 | -6.30 | NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O | https://pubmed.ncbi.nlm.nih.gov/30011231 | |
vanillin | 3971 | None | 0 | Human | Functional | pEC50 | = | - | 3.28 | 1 | 3 | Unclassified | Guide to Pharmacology | 152.0 | 2 | 1 | 3 | 1.21 | COc1cc(C=O)ccc1O | https://pubmed.ncbi.nlm.nih.gov/34307435 |
Showing 1 to 7 of 7 entries